March 24, 2020 / 12:43 PM / 6 days ago

BRIEF-Ampio Suspends Patient Enrollment In Its Phase 3 Study Of Ampion

March 24 (Reuters) - Ampio Pharmaceuticals Inc:

* AMPIO SUSPENDS PATIENT ENROLLMENT IN ITS PHASE 3 STUDY OF AMPION FOR SEVERE OSTEOARTHRITIS OF THE KNEE AND EXPLORES OTHER OPTIONS TO COMPLETE TRIAL

* AMPIO PHARMACEUTICALS INC - IT IS POSSIBLE THAT COVID-19 PANDEMIC MAY PREVENT COMPLETION OF AP-013 TRIAL AT THIS TIME OR AT ALL.

* AMPIO PHARMACEUTICALS INC - FOCUSING ON INVESTIGATING POTENTIAL USE OF NEBULIZED AMPION FOR TREATMENT OF A SERIOUS COMPLICATION OF COVID-19 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below